Results 191 to 200 of about 27,184 (256)

Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.

The Lancet HIV
BACKGROUND Although single-tablet, oral bictegravir, emtricitabine, and tenofovir alafenamide or dolutegravir and lamivudine are preferred regimens in several major guidelines and are widely used in many countries, they have not been compared in a fully ...
P. Ryan, J. L. Blanco, Mar Masiá, L. García-Fraile, M. Crusells, Pere Domingo, Adrià Curran, Roberto Guerri-Fernandez, E. Bernal, J. Bravo, B. Revollo, J. Macías, J. Tiraboschi, R. Montejano, C. Amador, Miguel Torralba, Dolores Merino, V. Diaz-Brito, M. J. Galindo, Sergio Ferra, Aroa Villoslada, J. Losa, F. Fanjul, Xavier Perez-Stachowski, Joaquim Peraire, Joaquín Portilla, Sara de la Fuente, Carlos Dueñas, Maria J Vazquez, Silvana Di Gregorio, H. Esteban, P. Gil, M. de Miguel, B. Alejos, Esteban Martínez   +34 more
semanticscholar   +1 more source

Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study

Frontiers in Pharmacology
Background/aim Tenofovir amibufenamide (TMF) has demonstrated significant antiviral activity and safety in individuals with chronic hepatitis B (CHB) in randomized clinical trials. The purpose of this study was to investigate the effectiveness and safety
X. Qiu, Yue Yin, Shibin Zhang, Wei Liu
semanticscholar   +1 more source

Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta‐Analysis

Journal of Medical Virology
Tenofovir alafenamide (TAF) is widely used for chronic hepatitis B (CHB) treatment due to its improved renal and bone safety compared to tenofovir disoproxil fumarate (TDF).
Ping-Yu Hsu, Hui-Chen Su, Mi-Chia Ma, Chien-An Chen, Sin-Yi Yu, Yi-Ming Hua   +5 more
semanticscholar   +1 more source

Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV

Infectious Disease and Therapy
Transient viremia can occur in people with human immunodeficiency virus (HIV), often referred to as people with HIV (PWH), and is sometimes related to poor adherence to antiretroviral therapy (ART).
A. Pozniak, C. Orkin, Y. Yazdanpanah, Axel Baumgarten, K. Mounzer, M. D’Antoni, Hailin Huang, Hui Liu, Kristen N. Andreatta, Laurie A Vanderveen, Christian Callebaut, J. Hindman, J. Arribas   +12 more
semanticscholar   +1 more source

Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial

Clinical Infectious Diseases
Background Doravirine/islatravir is an investigational regimen that is being studied for human immunodeficiency virus type 1 (HIV-1) treatment. Methods In this phase 3, double-blind, double-dummy trial (ClinicalTrials.gov NCT04233879), previously ...
Jürgen K Rockstroh, R. Paredes, P. Cahn, Jean-Michel Molina, Simiso M Sokhela, F. Hinestrosa, S. Kassim, Douglas Cunningham, J. Ghosn, J. Bogner, H. Gatanaga, Ernest Asante-Appiah, Ying Zhang, Uchechukwu Nwoke, Stephanie O Klopfer, Karen Eves, Kathleen Squires, Todd Correll, Michelle C Fox, Mary L Pisculli   +19 more
semanticscholar   +1 more source

Bictegravir/emtricitabine/tenofovir alafenamide after virologic failure to cabotegravir/rilpivirine

AIDS (London)
Bictegravir/emtricitabine/tenofovir alafenamide after virologic ...
Pierre Giguère, Kyla Agtarap, Michaeline McGuinty, C. Touchie, Steve Kravcik, Jonathan B. Angel   +5 more
semanticscholar   +1 more source

Incidences of Virological and Clinical Relapses After Cessation of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, or Entecavir in Patients With HBeAg‐Negative Chronic Hepatitis B

Journal of Gastroenterology and Hepatology
The relapse pattern following the discontinuation of tenofovir alafenamide (TAF) in patients with chronic hepatitis B (CHB) remains unclear. This study aimed to compare the 2‐year incidences of virological and clinical relapses among patients who ...
Cheng-Hao Tseng, Teng-Yu Lee, Chi-Yi Chen, Chung-Feng Huang, Po-Yueh Chen, Tyng-Yuang Jang, Tzeng‐Huey Yang, Chia-Ching Wu, Yao-Chun Hsu   +8 more
semanticscholar   +1 more source

Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B

Alimentary Pharmacology and Therapeutics
Mothers with chronic hepatitis B and advanced fibrosis may require antiviral therapy throughout pregnancy. Current guidelines recommend tenofovir disoproxil fumarate (TDF), which is unsuitable for mothers at risk of renal dysfunction or decreased bone ...
Xingfei Pan, Liyang Zhou, Jing Hu, Panpan Zhai, X. Ou, Fang He, Calvin Q. Pan   +6 more
semanticscholar   +1 more source

Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD Study

Open Forum Infectious Diseases
Background In TANGO and SALSA, switching to dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing a baseline regimen among adults who were treatment experienced, although few switched from bictegravir (B) / emtricitabine (F) / tenofovir ...
Charlotte-Paige Rolle, Jamie Castano, V. Nguyen, F. Hinestrosa, E. Dejesus   +4 more
semanticscholar   +1 more source

Tenofovir alafenamide

Reactions Weekly, 2022
  +4 more sources